Lymphoid tyrosine phosphatase R620W variant and inflammatory bowel disease in Tunisia

Table 1 Clinical characteristics and serological markers of CD and UC

CD patients	n = 105
Sex	55 men and 50 women
Mean age (yr)	36 ± 10.2
Age at diagnosis (yr)	31.2 ± 12.8
Disease location
Ileitis (%)	27 (25.7)
Ileocolitis (%)	54 (51.5)
Colitis (%)	24 (22.8)
Anal involvement (%)	44 (42)
Extra-intestinal manifestations (%)	20 (19.04)
(peripheral arthritis and/or ankylosing spondylitis)
ASCA (%)	47 (44.8)
UC patients	n = 59
Sex	17 men and 42 women
Mean age (yr)	38 ± 12.4
Age at diagnosis (yr)	36.3 ± 10.8
Disease extent
Pancolitis (%)	38 (64.4)
Distal colitis (%)	21 (35.6)
Extra-intestinal manifestations (%)	3 (5.1)
Primary sclerosing cholangitis
p-ANCA (%)	16 (27.1)

CD: Crohn’s disease; UC: Ulcerative colitis; ASCA: Anti-Saccharomyces cerevisiae antibodies; p-ANCA: Perinuclear anti-neutrophil cytoplasmic antibodies.

Table 2 Genotype and allele frequencies of PTPN22 polymorphism in controls and patients

Groups	n	Genotype frequency			Allele frequency		P
		R/R	R/W	W/W	R	W
Controls (%)	100	98 (98)	2 (2)	0 (0)	0.990	0.010	P/C: 0.00001 (OR: 17.81 CI 95%: 4.18-21.86)
IBD patients (%)	164	114 (69.5)	50 (30.5)	0 (0)	0.848	0.152
CD (%)	105	68 (64.8)	37 (35.2)	0 (0)	0.823	0.177
UC (%)	59	46 (78)	13 (22)	0 (0)	0.889	0.111	CD/UC: NS

P: Patients; C: Controls; NS: Not significant.